Disease · MONDO_0007691

Guillain-Barre syndrome, familial

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Guillain-Barre syndrome, familial. Diseases, record MONDO_0007691. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007691

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Guillain-Barre syndrome, familial
Open Targets ID: MONDO_0007691
Other names: AIDP, CIDP, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, neuropathy, inflammatory demyelinating, polyneuropathy, inflammatory demyelinating, acute
Highest stage of its drugs: Phase 3, for 7 of its 16 drugs, from ClinicalTrials.gov and TTD

Source Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	17	17	5	Drugs and targets
RILIPRUBART	CHEMBL5315038	Antibody	Phase 3	ClinicalTrials.gov	5	4	4	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
EMPASIPRUBART	CHEMBL5314673	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RIPERTAMAB	CHEMBL4594604	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
NIPOCALIMAB	CHEMBL4594310	Antibody	Phase 3	TTD	2	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
EFGARTIGIMOD ALFA	CHEMBL4297551	Protein	Phase 2	ClinicalTrials.gov	3	3	2	Drugs and targets
BATOCLIMAB	CHEMBL4650514	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FCGRT	IgG receptor FcRn large subunit p51	4	IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitor	Phase 3	https://conductscience.org/library/genes/2217	Drugs and targets
MC2R	Adrenocorticotropic hormone receptor	1	Melanocortin receptor 2 agonist	Phase 2	https://conductscience.org/library/genes/4158	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	1	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets

Trials29

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 11 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04281472	A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)	Phase 2	322	2024-08-20	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov
NCT01545076	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)	Phase 3	208	2018-07-05	Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy	HUMAN IMMUNOGLOBULIN G	Its record names the disease	ClinicalTrials.gov
NCT02638207	Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy	Phase 3	142	2021-02-16	Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy	HUMAN IMMUNOGLOBULIN G	Its record names the disease	ClinicalTrials.gov
NCT02027701	Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Phase 3	82	2018-10-02	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	HUMAN IMMUNOGLOBULIN G	Its record names the disease	ClinicalTrials.gov
NCT00278629	Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy	Phase 2	80	2020-07-23	Chronic Inflammatory Demyelinating Polyneuropathy	CYCLOPHOSPHAMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02465359	Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Not applicable	15	2024-10-08	Chronic Inflammatory Demyelinating Polyneuropathy	HUMAN IMMUNOGLOBULIN G	Its record names the disease	ClinicalTrials.gov
NCT00962429	Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy	Phase 2	7	2020-08-19	CIDP, Chronic Inflammatory Demyelinating Polyneuropathy	LIPOIC ACID, ALPHA	Its record names the disease	ClinicalTrials.gov
NCT06859099	Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP	Phase 3	300		Polyneuropathy, Inflammatory Demyelinating, Chronic	RILIPRUBART	Its record names the disease	ClinicalTrials.gov
NCT04280718	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)	Phase 2	229		Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov
NCT06920004	A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP	Phase 3	218		Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy	EMPASIPRUBART	Its record names the disease	ClinicalTrials.gov

1 to 10 of 29

See all 29 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Stage B: Efgartigimod PH20 SC vs Stage B: Placebo PH20 SC: Stage B: Number of Participants With Improved Functional Level Compared to Stage B Baseline	50 of 111	40 of 110	221	NCT04281472

Source Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32594300	RESULT	1	PubMed
15703014	RESULT	1	PubMed
12084892	RESULT	1	PubMed
42578463	DERIVED	1	PubMed
39304241	DERIVED	1	PubMed
38353301	DERIVED	2	PubMed
38205888	DERIVED	1	PubMed
37378806	DERIVED	1	PubMed
37119056	DERIVED	1	PubMed
35038723	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007691

GET https://conductscience.org/api/diseases/v1/MONDO_0007691/trials?page=2

API reference For AI assistants